# Jigar Raythatha

> Jigar Raythatha is a Series B investor at Third Rock Ventures backing Health Care and Life Science. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures)
- Location: Boston, United States
- Total investments: 2
- Last investment: Jun 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jigar-raythatha
- Website: https://x.com/jraythatha
- Facebook: https://www.facebook.com/jraythatha

Jigar Raythatha is a Series B investor at Third Rock Ventures in Boston focused on Health Care and Life Science. Jigar Raythatha is based out of Boston, Massachusetts and is the Partner of Third Rock Ventures. Jigar previously worked at Jounce Therapeutics, Inc as a Chair of the Board of Directors. Jigar Raythatha attended the Columbia Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M | Series C | Jun 30, 2026 |  |
| Flare Therapeutics | Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $123M | Series B | Mar 22, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 2 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [Eli Lilly](https://shizune.co/investors/profile/eli-lilly) — VC Fund, 2 deals together
- [Eventide](https://shizune.co/investors/profile/eventide-asset-management) — VC Fund, 2 deals together
- [GordonMD Global Investments](https://shizune.co/investors/profile/gordonmd-global-investments) — VC Fund, 2 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 2 deals together

## About Third Rock Ventures

VC Fund · Boston, United States

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

5 contacts available at Third Rock Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Cary Pfeffer | Partner | https://shizune.co/investors/profile/cary-pfeffer |
| Jeff Tong | Partner | https://shizune.co/investors/profile/jeff-tong |
| Jigar Raythatha | Partner | https://shizune.co/investors/profile/jigar-raythatha |
| Mark Levin | Partner | https://shizune.co/investors/profile/mark-levin |
| Reid Huber | Partner | https://shizune.co/investors/profile/reid-huber |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Jigar Raythatha invest in?

Jigar Raythatha invests primarily in Health Care, Life Science and Biotechnology startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jigar Raythatha last invest?

The most recent investment recorded for Jigar Raythatha closed in Jun 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co